Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome |
Choi, Eun-Ji
(Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine)
Lee, Je-Hwan (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Lee, Jung-Hee (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Park, Han-Seung (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Ko, Sun-Hye (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Seol, Miee (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Lee, Young-Shin (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Kang, Young-Ah (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Jeon, Mijin (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) Lee, Kyoo-Hyung (Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine) |
1 | Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1713-8. DOI |
2 | Kekre N, Koreth J. Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes. Curr Opin Hematol 2015;22:116-22. DOI |
3 | Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007;21:2540-4. DOI |
4 | Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381-9. DOI |
5 | Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013;27:1229-35. DOI |
6 | Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25. DOI |
7 | Guieze R, Damaj G, Pereira B, et al. Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies. Biol Blood Marrow Transplant 2016;22:240-7. DOI |
8 | Sauer T, Silling G, Groth C, et al. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. Bone Marrow Transplant 2015;50:485-92. DOI |
9 | Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2014;20:1785-90. DOI |
10 | Orti G, Sanz J, Bermudez A, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: A Retrospective Cohort on Behalf of the Grupo Espanol de Trasplante Hematopoyetico. Biol Blood Marrow Transplant 2016;22:584-8. DOI |
11 | Krishnamurthy P, Potter VT, Barber LD, et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013;19:562-8. DOI |
![]() |